Form 8-K

8-K — Vogenx, Inc.

Accession: 0001185185-26-004679

Filed: 2026-10-09

Period: 2026-10-07

CIK: 0001903784

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — vogenx8k100826.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (vogenxex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: vogenx8k100826.htm · Sequence: 1

false

0001903784

2026-10-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 7, 2026

VOGENX, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-43441

86-3697324

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

Vogenx,

Inc.

Box 19469

Raleigh,

North Carolina

27619

(Address of principal executive offices)

(Zip Code)

(919) 659-5677

(Registrant’s

telephone number, including area code)

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, $0.0001 par value per share

VOGX

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Richard Gorman as a Director

and Employment as Chief Commercial Officer

On October 7, 2026, concurrent with his becoming

an employee of Vogenx, Inc. (the “Company”) as Chief Commercial Officer, Richard Gorman resigned from the Board of Directors

(“Board”) of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation

Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026. Mr. Gorman’s resignation was not the

result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 7.01.

Regulation FD Disclosure.

On October 9, 2026, the Company issued a press

release announcing the resignation of Richard Gorman from the Board and his employment as the Company’s Chief Commercial Officer.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report

on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall

it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended,

except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release, dated October 9, 2026, announcing the appointment of Richard Gorman as Chief Commercial Officer

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Vogenx, Inc.

Date: October 9, 2026

By:

/s/ James Green

Name:

James Green

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: vogenxex99-1.htm · Sequence: 2

Exhibit 99.1

VOGENX, INC.

3901 Barrett Drive, Suite 300 |

Raleigh, North Carolina 27609 | Nasdaq: VOGX

FOR IMMEDIATE RELEASE

Vogenx Appoints Board Member Richard Gorman as Chief Commercial

Officer

Thirty-year biopharmaceutical commercial leader

transitions from the Board of Directors to Chief Commercial Officer

Appointment strengthens corporate strategy, business

development and commercial readiness as the Company advances mizagliflozin following its August 2026 initial public offering

RALEIGH, N.C., October 9, 2026 / Vogenx, Inc. (Nasdaq: VOGX),

a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced

that Richard “Rich” Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026. Concurrent

with his joining the management team, Mr. Gorman, who has served as an independent member of the Vogenx Board of Directors since 2022,

will resign as a member of the Board and its committees. Vogenx will conduct a search to identify a new independent director to join the

Board.

In this newly created role, Mr. Gorman will lead commercial operations

and corporate strategy for Vogenx, including market development for post-bariatric hypoglycemia (PBH), gastroparesis, and long-range portfolio

planning across the Company’s pipeline. Mr. Gorman will initially also be responsible for business development activities, including

partnering and licensing strategy.

“Rich has been a trusted voice in our boardroom since 2022 and

has helped shape the strategy that carried this Company from its early days through to the public markets,” said James Green, Chief

Executive Officer and Chairman of the Board of Vogenx. “As we prepare to move mizagliflozin into later-stage development, the questions

in front of us will be increasingly commercial ones: how we define these markets and how we prepare to reach patients who today have limited

or no FDA-approved drug treatment options. Bringing Rich across the table and onto the management team is the clearest way to answer them.”

About Richard Gorman

Mr. Gorman is a 30-year commercial leader

in the life sciences industry who has supported more than 25 product launches in the U.S. and international markets, including rare disease

and specialty products, with peak sales ranging from $350 million to more than $3 billion. He has guided development-stage companies

through each element of the transition to successful commercial execution: building commercial infrastructure, establishing distribution

models, developing pricing and market access strategies, and meeting the regulatory requirements for launch. His experience includes

several metabolic disease launches, among them the U.S. launch strategy for one of the first GLP-1 receptor agonists. Most recently,

following the combination of Envision Pharma Group’s Two Labs and Strategic Consulting units, he served as President, Life Science

Commercialization and Strategic Consulting at Envision, where he led strategic consulting for launch readiness, health economics and

pricing strategy for emerging biopharma companies bringing their first product to market. Previously, he was Chief Commercial Officer

and Global Head of Strategy at Amplity Health and Global Head of Commercial Business Development at Syneos Health where he shaped end-to-end

clinical and commercial plans for biopharma clients, from pre-approval medical communications through post-approval commercial operations

deployment and launch. Earlier, he served as Chief Executive of a specialty pharmaceutical company and held senior leadership roles at

Andrx Pharmaceuticals, Thergen, Tiber Laboratories and Gorbec Pharmaceutical Services. He began his career in sales and marketing at

Marion Laboratories. Mr. Gorman holds a B.S. from John Carroll University and an M.B.A. from the University of South Florida.

“I have spent years watching this team do a great deal in a capital

efficient manner, and the need for mizagliflozin has only gotten stronger,” said Mr. Gorman. “PBH and gastroparesis are serious,

underserved conditions with limited pharmacological options, and I am glad to be joining the leadership team at this pivotal time for

the Company.”

About Vogenx, Inc.

Vogenx, Inc. (Nasdaq: VOGX) is a clinical-stage biopharmaceutical company

based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious metabolic

and gastrointestinal diseases with high unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric

hypoglycemia, gastroparesis and GIP-dependent Cushing’s Syndrome. For more information, please visit https://vogenx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s leadership transition, corporate

and commercial strategy, anticipated clinical development plans and timelines, the anticipated use of proceeds from the Company’s

initial public offering, and the potential market opportunity for its product candidates. Words such as “anticipate,” “believe,”

“expect,” “intend,” “plan,” “potential,” “will” and similar expressions are

intended to identify forward-looking statements. These statements are based on management’s current expectations and are subject

to risks and uncertainties that could cause actual results to differ materially, including risks related to the initiation, timing and

results of clinical trials, regulatory review, the Company’s ability to establish sales, marketing and commercial capabilities,

reliance on third parties and the Company’s license from Kissei Pharmaceutical Co., Ltd., the Company’s need for additional

capital, its limited operating history, and its dependence on a small number of key personnel. Additional information on these and other

risks is contained in the Company’s filings with the Securities and Exchange Commission, including the prospectus filed pursuant

to Rule 424(b)(4) on August 12, 2026 and subsequent periodic reports. Forward-looking statements speak only as of the date of this release,

and Vogenx undertakes no obligation to update them except as required by law.

Contacts

Harrison Seidner, PhD and Nilesh Talele,

PhD

WaterSeid Partners, Inc.

ir@vogenx.com

SOURCE: Vogenx, Inc.

# # #

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 07, 2026

Entity File Number

001-43441

Entity Registrant Name

VOGENX, INC.

Entity Central Index Key

0001903784

Entity Tax Identification Number

86-3697324

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Box 19469

Entity Address, City or Town

Raleigh

Entity Address, State or Province

Entity Address, Postal Zip Code

27619

City Area Code

919

Local Phone Number

659-5677

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

VOGX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration